Welcome to our dedicated page for Sutro Biopharma SEC filings (Ticker: STRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sutro Biopharma, Inc. (STRO) SEC filings page on Stock Titan provides access to the company’s public filings as reported to the U.S. Securities and Exchange Commission. Sutro is a clinical-stage oncology company focused on antibody-drug conjugates (ADCs), and its filings offer detailed insight into how it reports financial results, manages risk, and discloses material events related to its ADC pipeline and corporate operations.
Investors can review current reports on Form 8-K, where Sutro has disclosed items such as quarterly financial results, organizational restructuring designed to prioritize its ADC programs and extend its cash runway, and notices from Nasdaq regarding minimum bid price compliance. Additional 8-K filings describe actions like the 1-for-10 reverse stock split of its common stock and subsequent confirmation that the company regained compliance with Nasdaq Listing Rule 5450(a)(1).
Beyond event-driven 8-Ks, users can use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more extensive information on Sutro’s research and development activities, collaboration agreements, and financial condition. For those tracking management and ownership changes, insider transaction reports on Form 4 and related filings can also be accessed to see how executives and directors transact in STRO shares.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as pipeline updates, restructuring charges, collaboration revenue, and listing status developments. Real-time updates from EDGAR ensure that new Sutro Biopharma filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full SEC documents.
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, acquired equity and vested awards on 09/18/2025. The Form 4 shows 37,500 restricted stock units (RSUs) were recorded as acquired and will settle into common stock; each RSU converts to one share on settlement. Following the transactions, Mr. Gerber beneficially owned 75,000 shares of common stock. Additionally, the issuer withheld 13,417 shares
David Pauling, Chief Administrative Officer and General Counsel of Sutro BioPharma, Inc. (STRO), amended his Form 3 to correct the number of shares he beneficially owns. The filing reports 56,733 shares of common stock held directly. The amendment notes the original Form 3 filed on April 8, 2025 misstated the total and is otherwise unchanged. The event date requiring the statement is 04/04/2025, and the amended Form 3/A is signed by Mr. Pauling on 09/12/2025.
Barbara Leyman, Chief Business Officer of Sutro Biopharma, reported changes in her holdings on Form 4. She received 25,000 restricted stock units (RSUs) on 07/08/2025 that vest in four equal annual installments beginning 07/08/2025, and those RSUs convert to common stock upon settlement. Following the reported transactions, she beneficially owns 75,000 RSUs. Separately, 8,944 shares of common stock were withheld by the issuer to satisfy tax withholding related to a net settlement of RSUs; this withholding is not a sale by the reporting person. After the withholding and the reported acquisition, she directly beneficially owns 16,056 shares of common stock.
Jane Chung, Chief Executive Officer and Director of Sutro Biopharma, Inc. (STRO), reported insider activity on Form 4 dated 08/26/2025 covering transactions with an earliest date of 08/09/2025. The filing shows the vesting of 18,750 restricted stock units (RSUs) that settled into 18,750 shares of common stock (transaction code M), increasing her beneficial ownership to 117,058 shares. The issuer withheld 6,708 shares
The filers RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah submitted an amendment to Schedule 13G for Sutro Biopharma, Inc. (CUSIP 869367102) reporting ownership information as of June 30, 2025. The filing states that each reporting person beneficially owns 0.00 shares and holds 0.0% of the class. The filers expressly disclaim being a group and identify their principal business address as c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116. The filing includes a joint filing agreement incorporated by reference.
Suvretta Capital Management, Averill Master Fund and Aaron Cowen filed an amended Schedule 13G reporting shared beneficial ownership of Sutro Biopharma common stock equal to approximately 6.49 million shares for Suvretta/Cowen and 6.46 million shares for Averill, each representing 7.7% of the class. The filing shows no sole voting or dispositive power and instead reports shared voting and dispositive power for the reported shares. The filing states these securities are directly owned by advisory clients of Suvretta and that, other than Averill, no advisory client is deemed to beneficially own more than 5% of the class. The reporting persons disclaim beneficial ownership except for pecuniary interests and certify the holdings were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
